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Abstract
Introduction:  Chronic  obstructive  pulmonary  disease  (COPD)  is  currently  a  complex,  multi-
component  disorder.  The  COPD  Assessment  Test  (CAT)  has  been  increasingly  used  to  assess
COPD patients.  This  study  aims  to  investigate  the  relationship  between  CAT  and  inﬂammation
markers and  other  COPD  components.
Methods:  We  enrolled  110  stable  COPD  patients  and  65  control  subjects  in  this  study.  All  patients
completed  the  CAT  questionnaire  and  the  modiﬁed  Medical  Research  Council  (mMRC)  disp-
nea scale.  The  quality  of  life  of  these  patients  was  measured  with  St.  George’s  Respiratory
Questionnaire  (SGRQ).  Levels  of  TNF, IL-6,  CRP  were  determined  in  blood  samples.
Results: In  COPD  patients,  serum  levels  of  TNF  (109.5  ±  58  pg/ml),  IL-6  (10.3  ±  18  pg/ml),  and
C-reactive  protein  (CRP)  (1.6  ±  1.7  mg/L)  were  found  to  be  signiﬁcantly  higher  compared  to
controls (TNF-:  14.6  ±  18  pg/ml,  IL-6:  2.14  ±  1.9  pg/ml,  CRP:  0.4  ±  0.3  mg/L,  p  <  0.001).  These
markers were  correlated  with  smoking  (r  from  0.27  to  0.35,  p  <  0.001),  FEV1 (r  from  −0.39
to −0.57,  p  <  0.001),  FVC  (r  from  −0.32  to  −0.37,  p  <  0.001)  and  FEV1/FVC  (r  from  −0.31  to
−0.66, p  <  0.001).  The  CAT  score  correlated  with  GOLD  spirometric  stages,  mMRC  dyspnea  score,
number of  exacerbations  in  the  previous  year  and  FEV1 (p  <  0.001).  There  was  a  signiﬁcant  cor-
relation between  levels  of  CRP  and  the  CAT  score  (r  =  0.43,  p  <  0.001)  but  no  similar  relationship
between levels  of  TNF  and  IL-6  and  the  CAT  was  observed.
Conclusion:  Systemic  inﬂammation  persists  in  the  stable  period  of  COPD.  CRP,  one  of  the  inﬂam-
mation markers,  was  correlated  with  the  CAT.  Further  studies  are  required  to  conﬁrm  the
relationship  between  CAT  and  biomarkers.
©  2015  Sociedade  Portuguesa  de  Pneumologia.  Published  by  Elsevier  España,  S.L.U.  All  rights
reserved.∗ Corresponding author.
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hronic  obstructive  pulmonary  disease  (COPD)  is  a  signif-
cant  cause  of  mortality  and  morbidity  across  the  modern
orld.  The  mortality  rate  of  this  disease  is  increasing  and
t  is  predicted  that  it  will  become  the  third  leading  cause
f  death  worldwide  by  2020.1 It  is  not  possible  to  deﬁne
OPD  based  solely  on  forced  expiratory  volume  in  the  1s
FEV1)  so  the  Global  Initiative  for  Chronic  Obstructive  lung
isease  (GOLD)  has  devised  a  multidimensional  deﬁnition  to
ssess  COPD.2 The  new  deﬁnition  includes  the  prevalence
f  symptoms  and  the  previous  history  of  exacerbations  in
ddition  to  the  FEV1 value  and  also  emphasizes  the  assess-
ent  of  comorbidities.  In  order  to  assess  for  symptoms,
ither  the  modiﬁed  Medical  Research  Council  (mMRC)  or  the
OPD  Assessment  Test  (CAT)  is  recommended.  Additionally,
 disease-speciﬁc  quality  of  life  scale  (SGRQ,  SF-36,  CCQ)
as  used  to  evaluate  the  impact  of  the  disease  on  daily
ife.  Some  studies  have  demonstrated  a  strong  relationship
etween  CAT  and  St.  George’s  Respiratory  Questionnaire
SGRQ).3,4 Ladeira  et  al.5 showed  that  CAT  was  correlated
o  the  BODE  index.
COPD  is  a  complex  disease  and  includes  genetic,  cellu-
ar  and  molecular  components.  There  are  many  different
ells  and  molecules  involved  in  the  inﬂammatory  path-
ays.  Several  indicators  have  been  used  to  demonstrate  a
otential  disease-related  systemic  inﬂammation.6--9 Airway
nd  lung  parenchymal  inﬂammation  is  a  major  pathogenic
echanism  of  COPD.  In  addition,  persistent  systemic  inﬂam-
ation  may  be  associated  with  a  various  extrapulmonary
omorbidities  and  pulmonary  effects.10 Recent  research  has
rovided  proof  of  the  existence  of  distinct  ‘‘novel  systemic
nﬂammatory  COPD  phenotype.’’ 7 In  a  recent  study,  it  has
een  shown  that  cardiovascular  comorbidity  and  diabetes
ere  associated  with  higher  levels  for  some  markers  of
ystemic  inﬂammation.11 Therefore,  genetic  load,  systemic
nﬂammation  and  comorbid  diseases  are  associated  with
arious  phenotypes  in  COPD.  It  is  essential  that  new  per-
pectives  should  be  developed  in  the  management  of  this
isease.
Currently,  CAT  has  been  used  increasingly  for  assessing
nd  monitoring  COPD.  Although  several  serum  biomarkers
ave  been  deﬁned  in  COPD,  there  is  not  one  single  sufﬁ-
ient  and  effective  single  biomarker  that  can  be  used  to
ssess  the  status  of  COPD  patients.  It  has  been  shown  that
iomarkers  are  associated  with  several  parameters  such  as
nﬂammation,  hospitalization,  and  mortality.7--13 However,
he  relationship  between  CAT  and  biomarkers  has  not  been
learly  demonstrated.  Therefore,  the  present  study  aims  to
nvestigate  the  levels  of  systemic  inﬂammation  in  COPD  and
etermine  the  relationship  between  CAT  and  inﬂammation
arkers  and  quality  of  life.
aterials and methods
tudy  designhis  was  a  cross-sectional  single-visit  observational  study.
ne  hundred  and  ten  patients  with  COPD  diagnosed  accord-
ng  to  GOLD  criteria14 and  sixty-ﬁve  control  subjects  were
ecruited  between  February  2013  and  August  2013.  Control
s
t
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ubjects  were  chosen  from  those  referred  to  a  pulmonology
nd  internal  medicine  clinic  at  Balikesir  University  Hospital,
ndergoing  routine  investigations.  Written  informed  con-
ent  was  obtained  from  all  participants  and  the  study  was
pproved  by  the  Institutional  Ethics  Committee  of  the  Fac-
lty  of  Medicine  at  Balikesir  University.
All  patients  were  subjected  to  physical  examination,
hest  X-ray,  respiratory  function  test,  and  routine  blood
nalysis  tests.  The  number  of  exacerbations  in  the  previous
ear  and  the  history  of  smoking  were  recorded.  The  CAT,
MRC  dyspnea  score  was  carried  out  via  face-to-face  inter-
iews  by  pulmonary  specialist.  SGRQ  scores  were  reported
y  the  patients.  For  the  healthy  control  group  only  a  respi-
atory  function  test  and  routine  blood  analysis  tests  were
one.
he  population  of  the  study
nclusion  criteria:  Patients  were  included  if  they;  (1)  were
lder  than  40  years;  (2)  were  current  or  ex-smokers  with
 smoking  history  ≥10  pack-years;  (3)  exhibited  a  post-
ronchodilator  FEV1 <  80%  and  an  FEV1/FVC  <  0.7.  Control
ubjects  were  included  if  they:  (1)  were  older  than  40
ears;  (2)  were  free  from  lung  disease  as  determined  by
 physician;  (3)  had  a  normal  spirometry  (FEV1 >  85%  and
EV1/FVC  >  0.7);  and  (4)  had  a  smoking  history  of  <5  pack-
ear.
Exclusion  criteria:  Patients  were  excluded  who;  (1)  had
n  exacerbation  of  COPD  within  the  previous  6  weeks;  (2)
ad  a  respiratory  disorder  other  than  COPD  or  malignancy;
3)  had  a  chronic  inﬂammatory  disease  (vasculitis,  inﬂam-
atory  bowel  disease,  rheumatoid  arthritis  etc.)  (4)  had
ncontrolled  or  severe  concomitant  disease  (MI,  arrhythmia
tc.).
easurements
emographic  features,  age,  gender,  smoking  habits,  admis-
ion  to  an  emergency  service  or  hospitalization  over  the  past
ear,  accompanying  diseases,  and  existing  treatments  were
ll  recorded  appropriately.  We  deﬁned  an  exacerbation  as
orsening  of  symptoms  that  required  oral  corticosteroids
nd/or  antibiotics  and/or  hospitalization.  Comorbid  dis-
ases  were  established  using  the  clinical  history  and  physical
xamination  ﬁndings  during  the  visit  and  were  supported
y  a  review  of  the  available  medical  records.  Current
edications  including  inhalers,  antihypertensive  or  other
edications  were  documented.  The  height,  weight,  and
MI  indexes  were  measured,  and  a  spirometry  was  also
erformed  in  accordance  with  the  international  guidelines
ATS/ERS).15 The  disease  was  classiﬁed  according  to  the  old
nd  new  version  of  GOLD  staging.14 First,  GOLD  spirometric
taging  (FEV1 based  (1--4)  staging)  and  second,  GOLD  stag-
ng  (A--D  class).  Dyspnea  was  assessed  by  the  mMRC  dyspnea
cale.16 The  patients  with  COPD  were  categorized  into  A,  B,
 and  D  combining  symptom  assessment  by  mMRC  dyspnea
cores  and  exacerbation  risk.
CAT:  The  validity  and  reliability  of  the  Turkish  version  of
his  scale  has  been  previously  veriﬁed.17 The  CAT  includes
 items  and  yields  total  scores  ranging  from  0  to  40;  higher
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scores  indicate  a  more  severe  health  status  impairment  or
less  successful  control  of  COPD.3
Quality  of  life  Questionnaire:  The  quality  of  life  was
assessed  by  using  the  Turkish  translation  of  St.  George’s
Respiratory  Diseases  Questionnaire  (SGRQ).18
Biomarkers
We  chose  the  biomarkers  based  on  previous  studies.7,9--13
The  blood  samples  taken  from  all  subjects  were  centrifuged
and  stored  at  −80 ◦C.  All  samples  were  analyzed  when  the
study  was  completed.  The  serum  was  studied  in  a  diagnos-
tic  device  (BioTek,  ELx  800,  USA)  with  use  of  commercial
kits  (eBioscience,  Human  TNF- and  Human  IL-6  Platinum
ELISA,  Austria),  and  with  the  methods  of  tumor  necrosis
alpha  (TNF-) and  an  interleukin-6  (IL-6)  level  enzyme  linked
immunosorbent  assay  (ELISA).  The  levels  of  C-reactive  pro-
tein  (CRP)  were  evaluated  with  a  clinical  chemistry  analyzer
(Cobes  Integra  800,  Roche  diagnostics)  using  a  commercial
kit.  The  reference  value  of  CRP  is  0--0.5  mg/L,  while  the  ana-
lyzed  lowest  value  of  IL-6  is  0.92  pg/ml.  The  analyzed  lowest
value  of  TNF is  2.3  pg/ml.  TNF- and  IL-6  concentrations  of
some  samples  were  below  the  lower  limit  of  quantiﬁcation
(LLQ).  In  the  analysis  of  individuals  with  values  below  the
LLQ,  a  nominal  level  of  half  of  the  LLQ  value  was  used  to
avoid  a  downward  bias  of  the  population  data.19
Statistical  analysis
The  average  CRP  values  of  COPD  and  control  groups
(3.2  (1.5,7.1),  1.3  (0.6,2.7))  were  identiﬁed  from  similar
studies.7 After  that,  in  each  group,  the  sample  size  was
calculated  by  using  average  calculating  formula  with  80%
accuracy  and  5%  error.  Accordingly,  the  sample  size  was
found  to  be  at  least  55  subjects  in  each  group.  Results
are  presented  as  mean  ±  SD,  median,  or  percentage,  as
appropriate.  The  Student’s  t-test  and  ANOVA  were  used  for
parametric  tests;  the  Mann--Whitney  U-test,  Kruskal--Wallis
and  chi-square  statistics  were  used  for  non-parametric  tests
for  group  comparisons.  Fisher’s  exact  test  evaluated  the  dif-
ferences  between  the  percentages  of  comorbidities  and  the
differences  between  sexes.  The  chi-square  test  evaluated
the  differences  between  the  percentages  of  comorbidities.
Pair-wise  correlation  of  continuous  variables  in  patients  with
COPD  was  examined  by  Pearson  correlation.  A  value  of
p  <  0.05  was  considered  statistically  signiﬁcant.  All  statis-
tical  analyses  were  performed  with  the  SPSS  (version  20.0)
software.
Results
Clinical  characterization  of  subjects
The  study  included  110  patients  (mean  age  of  64  ±  8.9  years;
100  male  (90.9%)),  and  65  control  subjects  (mean  age  of
61.5  ±  9.2  years,  55  male  (84.6%)).  The  demographic  and
clinical  characteristics  of  the  patient  and  control  groups
are  given  in  Table  1.  Forty-ﬁve  (40.9%)  patients  with
COPD  had  an  accompanying  disease  (Ischemic  heart  dis-
ease  (n  =  21),  hypertension  (n  =  13),  diabetes  mellitus  (n  =  8),
other  (n  =  3)).  The  mean  FEV1 was  48.8%  of  the  predicted
value  and  mean  FEV1/FVC:  55.4%  in  the  COPD  group.  The
(
C
l
o13
ean  CAT  score  was  22.6  (±9.2),  mMRC:  1.9  (±0.9)  and  total
GRQ:  58.4  (±22.2).  Of  the  110  patients,  9.1%  were  stage  1,
7.3%  were  stage  2,  42.7%  were  stage  3,  10.9%  were  stage  4
ccording  to  GOLD  spirometric  staging.  When  patients  were
lassiﬁed  with  respect  to  GOLD  staging,  27.3%  were  group
,  30.9%  were  group  B,  7.3%  were  group  C  and  34.5%  were
roup  D.
OPD/control  comparisons
here  was  no  signiﬁcant  difference  between  the  ages
p  =  0.080,  Student’s  t-test)  and  sexes  of  the  two  groups
p  =  0.453,  ﬁsher’s  exact  test)  (Table  1).  The  groups  exhib-
ted  similar  incidences  of  comorbidities  (p  =  0.095,  2
est).  As  expected,  COPD  patients  had  signiﬁcantly  lower
ulmonary  function  parameters  (FEV1,  FVC,  FEV1/FVC)
ompared  to  controls  (p  <  0.001,  Student’s  t-test).  In
eneral,  COPD  patients  exhibited  higher  serum  levels
f  CRP  (1.6  ±  1.7  mg/L)  and  TNF- (109.5  ±  58  pg/ml)
nd  IL-6  (10.3  ±  18  pg/ml)  than  healthy  controls  (CRP:
.4  ±  0.3  mg/L,  p  <  0.001;  TNF-: 14.6  ±  18  pg/ml,  p  <  0.001;
L-6:  2.14  ±  1.9  pg/ml,  p  <  0.001,  Student’s  t-test)  (Table  1).
ssociation  of  CAT  questionnaires  and  patient
haracteristics
here  was  a correlation  between  the  CAT  score  and  the
OLD  spirometric  stage  (Pearson’s  r  =  0.43;  p  <  0.001).  The
AT  score  increased  in  parallel  with  disease  severity.  There
as  a  statistically  signiﬁcant  relationship  between  the  CAT
core  and  number  of  exacerbations  in  the  previous  year
Pearson’s  r  =  0.35,  p  <  0.001),  disease  duration  (Pearson’s
 =  0.29,  p  <  0.001),  smoking  (pack-year)  (Pearson’s  r  =  0.27,
 =  0.014)  and  mMRC  (Pearson’s  r  =  0.59,  p  <  0.001).  The
AT  score  was  found  to  be  signiﬁcantly  correlated  with
EV1 (Pearson’s  r =  −0.39,  p  <  0.001)  and  FVC  (Pearson’s
 =  −42,  p  =  0.003).  At  the  same  time,  a  strong  correlation
as  observed  between  the  CAT  score  and  the  SGRQ  symp-
om,  activity,  impact  and  total  scores  (Pearson’s  r  =  0.72;
 <  0.001).
ssociation  between  biomarkers  and  patient
haracteristics
nﬂammatory  markers  and  pulmonary  function  parameters
ere  compared.  As  the  FEV1 decreased,  levels  of  biomarker
ncreased  signiﬁcantly.  CRP  levels  were  correlated  with  FEV1
Pearson’s  r  =  −0.39,  p  < 0.001),  FVC  (Pearson’s  r  =  −0.33,
 <  0.001)  and  FEV1/FVC  (Pearson’s  r  =  −0.38,  p  <  0.001).
NF-  levels  were  also  correlated  with  FEV1 (Pearson’s
 =  −0.57,  p  <  0.001),  FVC  (Pearson’s  r  =  −0.37,  p  <  0.001)  and
EV1/FVC  (Pearson’s  r  =  −0.66,  p  <  0.001).  IL-6  levels  were
lso  correlated  with  FEV1 (Pearson’s  r  =  −0.31,  p  <  0.001),
VC  (Pearson’s  r  =  −0.32,  p  <  0.001)  and  FEV1/FVC  (Pear-
on’s  r  =  −0.34,  p  <  0.001).  A  signiﬁcant  correlation  was
bserved  between  CRP,  TNF-, IL-6  and  smoking  (pack-year)
Pearson’s  r =  0.35,  r  =  0.44,  r  =  0.27,  p  <  0.001,  respectively).
OPD  patients  with  cardiovascular  disease  had  an  increased
evel  of  CRP  (2.98  ±  2.4  mg/L)  compared  to  patients  with-
ut  comorbidities  (1.56  ±  1.5  mg/L,  p  =  0.008  ANOVA  test
14  N.  Sarioglu  et  al.
Table  1  Demographic,  functional,  clinical  features  of  the  patient  and  control  groups.
Patient  (n  =  110)  Control  (n  =  65)  p-value
Age  64.0  ±  8.9 61.5  ±  9.2 0.080
Male n,  (%)  100  (90.9)  55  (84.6)  0.224
BMI, kg/m2 26.5  ±  5.6  25  ±  2.6  0.064
Pack-years 38.9  ±  23  0.1  ±  1.2  <0.001
Co-morbidities,  n  (%)
Any  65  (59.1)  42  (64.6)  0.95
Ischemic heart  disease  21(19.1)  11  (16.9)
HT 13  (11.8)  6  (9.2)
DM 8  (7.3)  4  (6.2)
Other 3  (2.7) 2  (3.1)
mMRC 1.94  ±  0.9 0.04  ±  0.2 <0.001
FEV1,  %  predicted  48.8  ±  17.8  89.4  ±  5.6  <0.001
FVC, %  predicted  68.7  ±  17.8  92.1  ±  5.8  <0.001
FEV1/FVC,  % 55.4  ±  12.9  89.6  ±  4.7  <0.001
GOLD spirometric  stage,  n  (%)
1 10  (9.1)
2 41  (37.3)
3 47  (42.7)
4 12  (10.9)
GOLD stage,  n  (%)
A 30  (27.3)
B 34  (30.9)
C 8  (7.3)
D 38  (34.5)
SGRQ-total  score  58.4  ±  22.2
CAT score  22.6  ±  9.2
TNF (pg/ml)  109.5  ±  58  14.6  ±  18  <0.001
IL-6 (pg/ml)  10.3  ±  18  2.14  ±  1.9  <0.001
CRP (mg/L)  1.6  ±  1.7  0.4  ±  0.3  <0.001
Abbreviations: BMI, body mass index, HT: hypertension, DM: diabetes, FEV1: forced expiratory volume in 1 second, FVC: forced vital
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ollowed  by  LSD  post  hoc  test).  There  was  no  signiﬁcant
ssociation  with  other  biomarkers  and  comorbidities.  As  the
L-6  increased,  the  mMRC  score  increased,  but  this  rela-
ionship  was  not  statistically  signiﬁcant  (p  =  0.06).  When
nﬂammatory  markers  were  compared  with  CAT  score,  CRP
evels  were  shown  to  have  a  signiﬁcant  correlation  (r  =  0.43,
 <  0.001)  (Fig.  1)  while  no  correlation  was  observed  with
NF-  and  IL-6.  There  was  a  correlation  between  CRP  lev-
ls  and  TNF (r  = 0.48,  p  <  0.001).  No  direct  association  was
bserved  between  biomarkers  and  A-D  class  or  spirometric
tages.
iscussion
ome  assessment  tools  are  used  such  as  clinical  tests  (CAT,
ODE),  inﬂammation  markers  and  quality  of  life  question-
aires  to  evaluate  COPD.  It  is  commonly  accepted  that  a
ultidimensional  assessment  is  required  to  understand  and
anage  the  disease.  COPD  is  a  complex  disorder  with  a
ystemic  component  and  some  patients  appear  to  have  an
nﬂammatory  phenotype.  In  this  study,  CAT  was  performed
CRP (mg/L)
Figure  1  The  relationship  between  CAT  scores  and  CRP
(r =  0.43,  p  <  0.001).
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as  a  new  clinical  test,  and  the  relationship  of  CAT  with  other
COPD  components  was  investigated.
One  of  these  components  is  systemic  inﬂammation.  The
biomarkers  most  often  studied  in  COPD  to  indicate  sys-
temic  inﬂammation  which  are  commonly  used  are  CRP,  IL-6,
TNF-,  IL-8  and  ﬁbrinogen.  Several  studies  have  previously
reported  elevated  circulating  levels  of  these  markers  in
patients  with  stable  COPD.6--9,20--23 In  a  recent  study,  Agustí
et  al.  showed  that  30%  of  COPD  patients  did  not  present
evidence  of  systemic  inﬂammation  and  16%  of  the  patients
did  present  persistent  systemic  inﬂammation.7 Interestingly,
in  this  study,  the  serum  levels  of  TNF- and  IL-8  were
found  to  be  higher  in  smokers  with  normal  spirometry  com-
pared  to  COPD  patients.  The  other  markers  as  white  blood
cells,  IL-6,  CRP  and  ﬁbrinogen  were  found  to  be  higher  in
COPD  patients  than  in  the  smokers  with  normal  spirome-
try  and  non-smokers.  In  our  study,  the  levels  of  CRP,  TNF-,
IL-6  were  signiﬁcantly  higher  in  all  COPD  patients  when
compared  to  the  control  group.  All  the  biomarkers  were
found  to  be  correlated  with  the  cumulative  smoking  expo-
sure  and  reduction  of  pulmonary  function  test  parameters
(FEV1,  FVC,  and  FEV1/FVC).  The  biomarkers  level  relate
to  the  degree  of  airﬂow  obstruction.  These  results  are
consistent  with  those  reported  in  previous  cross  sectional
studies.13 In  another  study  which  examined  the  results  of
ECLIPSE,  cardiovascular  comorbidities  and  diabetes  were
correlated  with  some  systemic  inﬂammation  markers.9 In
our  study,  COPD  patients  with  cardiovascular  disease  had
an  increased  level  of  CRP  compared  to  patients  without
comorbidities.  Increased  systemic  inﬂammation  in  COPD
with  cardiovascular  diseases  support  a  pathophysiological
mechanism  between  COPD  and  these  comorbidities.
The  relationship  between  CAT  and  systemic  inﬂammation
has  not  been  clariﬁed  by  the  studies  conducted  so  far.  In  one
study,  a  signiﬁcant  correlation  was  shown  to  exist  between
the  LCN1,  LCN2  and  CAT.8 In  our  study,  a  signiﬁcant  rela-
tionship  has  been  shown  between  CAT  and  CRP.  However,  a
similar  correlation  could  not  be  shown  with  TNF- and  IL-6.
In  the  present  study,  COPD  patients  were  categorized
into  four  groups  (A--D)  and  stages  (1--4)  according  to  old
and  new  version  of  GOLD  classiﬁcation.  It  can  be  observed
that  Stage  1  and  Stage  4  constitute  the  smallest  proportion
of  the  population  with  10%  each  according  to  the  old  classi-
ﬁcation.  In  the  new  version,  the  population  was  distributed
almost  equally  among  groups  A,  B  and  D;  the  smallest  dis-
tribution  was  that  of  group  C.  In  other  studies,  it  has  also
been  shown  that  group  C  constitutes  the  smallest  propor-
tion  of  the  distribution.24,25 The  new  classiﬁcation  indicates
that  there  may  be  some  patients  with  multiple  symptoms
but  mild  airway  obstruction  as  well  as  some  patients  with
few  symptoms  but  with  severe  airway  obstructions.  Comor-
bidities  and  systemic  inﬂammation  can  lead  to  increases  in
exacerbation  and  symptoms  in  patients  with  mild/moderate
obstruction,  and  in  this  way,  it  causes  these  patients  to
be  placed  in  the  high  risk  groups  (C  or  D  class).  In  one
study,  it  was  shown  that  subtype  C  includes  patients  with
higher  comorbidity  status  and  subtype  D  includes  patients
with  the  most  severe  exacerbation,  a  high  rate  of  exacer-
bation  related  to  hospitalization  and  poorest  outcomes.26
In  a  recent  study,  Agustí  et  al.  compared  two  groups  with
and  without  persistent  systemic  inﬂammation  and  showed
that  patients  presenting  persistent  inﬂammation  during
P
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ollow-up  had  increased  exacerbation  rates  per  year  com-
ared  to  the  other  group  although  pulmonary  abnormalities
ere  similar  in  these  two  groups.7
GOLD  recommends  the  use  of  CAT  or  mMRC  scale  to
ssess  symptoms.  We  used  mMRC  scale  for  group  assign-
ent,  because  when  we  considered  the  symptoms  on  the
asis  of  CAT,  the  number  of  the  patients  with  less  than  10
reakpoints  was  very  small  (8  patients).  The  higher  CAT
cores  may  be  associated  with  the  higher  perceptions  of
atients’  symptoms.  It  was  also  shown  that  CAT  and  mMRC
re  not  equivalent,  and  this  may  cause  some  differences
n  classiﬁcation.24,25,27 In  the  new  classiﬁcation,  the  other
ut-off  points  are  composed  of  number  of  exacerbations
er  year.  The  relationship  between  basal  CAT  score  and
he  frequency  of  exacerbations  was  shown  in  the  COPD
atients.28 Pothirat  et  al.  have  shown  that  the  change  in
AT  score  during  monitoring  visits  is  a  useful  tool  for  detec-
ing  acute  deterioration  in  health  status  of  COPD  patients.29
n  our  study,  a  strong  relationship  was  observed  between
AT,  mMRC  and  the  exacerbation  rates.  The  CAT  was  also
ound  to  be  correlated  to  the  duration  of  illness,  and  smok-
ng  (pack-year).  The  mean  FEV1 of  the  patients  was  found  to
e  48.8%  of  the  predicted  value  and  the  mean  CAT  score  was
2.6.  A  strong  association  was  shown  between  CAT  and  FEV1,
VC  and  the  GOLD  spirometric  stage.  As  the  FEV1 and  FVC
ecreased,  the  CAT  score  increased.  The  CAT  score  also  pos-
tively  correlated  with  a  heavier  GOLD  stage.  These  results
how  that  CAT  reﬂects  the  severity  of  disease  very  well.
Another  important  component  of  COPD  management
s  quality  of  life.  A  variety  of  life-questionnaires  have
een  used  to  evaluate  the  effects  of  the  disease  on  daily
ife.  The  reliability  and  validity  of  the  Turkish  version  of
GRQ  has  been  proved.30 A  few  studies  have  shown  that
igniﬁcantly  correlation  was  observed  between  CAT  and
GRQ.3,4 In  a  study,  it  has  been  reported  that  CAT  is  sen-
itive  to  the  change  in  health  status  associated  with  COPD
xacerbations.31 In  our  study,  a  strong  relationship  was
hown  between  CAT  and  SGRQ.  Since  CAT,  compared  to
GRQ,  is  a  shorter  and  easier  test  to  understand,  the  use
f  CAT  is  more  practical.
The  present  study  has  several  limitations,  such  as  cross-
ectional  design,  a  single  center  study  and  small  sample  size.
n  addition,  the  inﬂammation  markers  could  not  be  com-
ared  in  smokers  who  have  normal  lung  function  because
hey  were  not  included  in  the  present  study.  The  medications
or  patients  may  exert  an  inﬂuence  on  systemic  inﬂamma-
ory  response  and  health  status  and  they  may  also  affect  the
esults.
In  summary,  CAT  is  a  test  that  can  be  used  in  the  assess-
ent  of  COPD,  since  its  reliability  and  validity  have  been
learly  demonstrated.  The  results  of  our  study  indicate  the
elationship  between  CAT  and  CRP  as  well  as  other  COPD
omponents  (clinical,  functional  parameters).  However,  lon-
itudinal  multicenter  studies  are  required  to  evaluate  the
elationship  between  CAT  and  biomarkers.rotection  of  human  and  animal  subjects.  The  authors
eclare  that  no  experiments  were  performed  on  humans  or
nimals  for  this  study.
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